News Updates

/News Updates/

A novel method for interrogating receiver operating characteristic curves…

Disease prevalence is rarely explicitly considered in the early stages of the development of novelprognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the keymetric to gauge and report predictive performance ability. Because this statistic does not account for diseaseprevalence, [...]

Professor Louise Kenny, Founding Director, wins Woman In Technology Award

Metabolomic Diagnostics wins Women Mean Business Woman In Technology Award WMB held its 11th annual Women Mean Business Conference & Awards in Dublin’s Shelbourne Hotel on the 2nd October last. The event recognises the achievements of businesswomen and entrepreneurs across Ireland. Opening the event, An [...]

Robin Tuytten serves on Advisory Board of HUPO 2017

Robin Tuytten, Metabolomic Diagnostics VP Research and Development serves on the Advisory Board of HUPO 2017 the 16th Annual World Congress of the Human Proteome Organisation which will be held in Dublin on 17-21st September 2017. HUPO2017 will bring together world leaders with a new [...]

Metabolomic Diagnostics: Adding to the our highly skilled team

Metabolomic Diagnostics are delighted to welcome Dr. Anna Suhr to the team in Cork, Ireland. Dr. Anna Suhr is a researcher specialized in the application of mass spectrometry in the clinical laboratory.  Her doctoral dissertation focused on the development and subsequent validation of novel mass spectrometric [...]

Robin Tuytten speaks at Bravo and Assaymap Bravo Interest Group

Robin Tuytten, Metabolomic Diagnostics VP Research and Development spoke at the recent Bravo and Assaymap Bravo Interest Group meeting September 2017. Robins talk was entitled ‘Translational metabolomics using AssayMAP and Bravo for operational set up’ This Meeting provided an excellent forum for attendees to share [...]

Metabolomic Diagnostics secures additional $2 million in venture funding

Metabolomic Diagnostics, has secured an additional €1.6 million in from investors to help complete PrePsia™, its new screening test for pre-eclampsia in first time pregnant mothers. This latest funding round is supported by existing investors, SOSventures, Enterprise Equity and Enterprise Ireland as well as a number [...]

Metabolomic Diagnostics Recruitment

Metabolomic Diagnostics have expanded its team by recruiting Paloma Muñiz Ortea and Leslie Brown. Ms. Muñiz Ortea is our R&D Product Development manager. Paloma is trained as an analytical chemist and holds a PhD from the Cork Institute of Technology where she developed analytical methods [...]

Preeclampsia Foundations’ Preeclampsia Awareness Month

As a nationally recognized health observance, Preeclampsia Awareness Month presents the perfect opportunity for the Preeclampsia Foundation to offer education and events that will increase awareness of this life-threatening hypertensive disorder of pregnancy, which occurs in up to eight percent of all pregnancies. The Preeclampsia [...]

Metabolomic Diagnostics to attend SRI 2016 in Montreal, Canada

Metabolomic Diagnostics’ Director of R&D, Dr. Robin Tuytten will attend the SRI’s 63rd Annual Scientific Meeting, which will take place at the Palais des congres de Montreal in Montreal, QC, Canada, from March 16 – 19, 2016. Prof. Louise Kenny of the Irish Centre for Fetal [...]

Dr. Robin Tuytten’s Webinar on Stratification For Pre-eclampsia

Yesterday afternoon, Metabolomic Diagnostics’ Director of R&D, Dr. Robin Tuytten, hosted a complimentary webinar on Stratification for Pre-eclampsia: Lessons Learned from Translation of a Metabolomics Discovery to a Robust LC-MS-20160229 1400-1. The event was hosted by the AACC and sponsored by Agilent Technologies. If you missed [...]

Load More Posts